|
1
|
Yao L, Du Y, Dong W, Gao X, Guo J, Qiu J,
Wei Q, Wu S, Ye D, Yu W, et al: Chinese quality control indices for
standardized diagnosis and treatment of renal cancer (2022
edition). J Natl Cancer Cent. 4:6–13. 2024.PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
3
|
Capitanio U, Bensalah K, Bex A, Boorjian
SA, Bray F, Coleman J, Gore JL, Sun M, Wood C and Russo P:
Epidemiology of renal cell carcinoma. Eur Urol. 75:74–84. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33.
2022.PubMed/NCBI
|
|
5
|
Lv XQ, Zhang KB, Guo X, Pei L and Li F:
Higher TYROBP and lower SOX6 as predictive biomarkers for poor
prognosis of clear cell renal cell carcinoma: A pilot study.
Medicine (Baltimore). 101:e306582022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Colombo PE, Quenet F, Alric P, Mourregot
A, Neron M, Portales F, Rouanet P and Carrier G: Distal
pancreatectomy with celiac axis resection (Modified Appleby
Procedure) and arterial reconstruction for locally advanced
pancreatic adenocarcinoma after FOLFIRINOX chemotherapy and
chemoradiation therapy. Ann Surg Oncol. 28:1106–1108. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Q, Ren H, Ge L, Zhang W, Song F and
Huang P: A review on the role of long non-coding RNA and microRNA
network in clear cell renal cell carcinoma and its tumor
microenvironment. Cancer Cell Int. 23:162023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Song Z, Guan C, Li T, Li C, Zhang N, Liu
K, Yang C, Zhu Y and Xu Y: Vaporization phosphorization-mediated
synthesis of phosphorus-doped TiO2 nanocomposites for
combined photodynamic and photothermal therapy of renal cell
carcinoma. J Mater Chem B. 12:4039–4052. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Meng K, Li YY, Liu DY, Hu LL, Pan YL,
Zhang CZ and He QY: A five-protein prognostic signature with GBP2
functioning in immune cell infiltration of clear cell renal cell
carcinoma. Comput Struct Biotechnol J. 21:2621–2630. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gao Y, Qi JC, Li X, Sun JP, Ji H and Li
QH: Decreased expression of TXNIP predicts poor prognosis in
patients with clear cell renal cell carcinoma. Oncol Lett.
19:763–770. 2020.PubMed/NCBI
|
|
11
|
Sánchez A and Fabregat I: Growth factor-
and cytokine-driven pathways governing liver stemness and
differentiation. World J Gastroenterol. 16:5148–5161. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sabaawy HE, Ryan BM, Khiabanian H and Pine
SR: JAK/STAT of all trades: linking inflammation with cancer
development, tumor progression and therapy resistance.
Carcinogenesis. 42:1411–1419. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Owen KL, Brockwell NK and Parker BS:
JAK-STAT signaling: A double-edged sword of immune regulation and
cancer progression. Cancers (Basel). 11:20022019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rah B, Rather RA, Bhat GR, Baba AB,
Mushtaq I, Farooq M, Yousuf T, Dar SB, Parveen S, Hassan R, et al:
JAK/STAT signaling: molecular targets, therapeutic opportunities,
and limitations of targeted inhibitions in solid malignancies.
Front Pharmacol. 13:8213442022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pang S, Zhao S, Dongye Y, Fan Y and Liu J:
Identification and validation of m6A-associated ferroptosis genes
in renal clear cell carcinoma. Cell Biol Int. 48:777–794. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiao W, Wang X, Wang T and Xing J:
Overexpression of BMP1 reflects poor prognosis in clear cell renal
cell carcinoma. Cancer Gene Ther. 27:330–340. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun J, Du Y, Zhang X, Wang Z, Lin Y, Song
Q, Wang X, Guo J, Li S, Nan J and Yang J: Discovery and evaluation
of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor,
selectively induces apoptosis of cancer cells with constitutively
activated STAT3. Invest New Drugs. 38:1003–1011. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dinakar YH, Kumar H, Mudavath SL, Jain R,
Ajmeer R and Jain V: Role of STAT3 in the initiation, progression,
proliferation and metastasis of breast cancer and strategies to
deliver JAK and STAT3 inhibitors. Life Sci. 309:1209962022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Groner B and von Manstein V: Jak Stat
signaling and cancer: Opportunities, benefits and side effects of
targeted inhibition. Mol Cell Endocrinol. 451:1–14. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang C, Wang Y, Hong T, Cheng B, Gan S,
Chen L, Zhang J, Zuo L, Li J and Cui X: Blocking the autocrine
regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the
progression and pazopanib resistance of clear cell renal cell
carcinoma. Cell Death Dis. 11:1172020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song J, Xu S, Zhang ZH, Chen YH, Gao L,
Xie DD, Sun GP, Yu DX and Xu DX: The correlation between low
vitamin D status and renal interleukin-6/STAT3 hyper-activation in
patients with clear cell renal cell carcinoma. Steroids.
150:1084452019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Arévalo J, Campoy I, Durán M, Nemours S,
Areny A, Vall-Palomar M, Martínez C, Cantero-Recasens G and
Meseguer A: STAT3 phosphorylation at serine 727 activates specific
genetic programs and promotes clear cell renal cell carcinoma
(ccRCC) aggressiveness. Sci Rep. 13:195522023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ganguly K, Rauth S, Marimuthu S, Kumar S
and Batra SK: Unraveling mucin domains in cancer and metastasis:
when protectors become predators. Cancer Metastasis Rev.
39:647–659. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang Y, Liu Z, Hu Y, Gao T, Wen T and An
G: Correlation of Tn antigen expression with mucins in Chinese
patients with colorectal cancer. Int J Clin Exp Pathol.
11:1562–1568. 2018.PubMed/NCBI
|
|
25
|
Miura K, Kinouchi M, Ishida K, Fujibuchi
W, Naitoh T, Ogawa H, Ando T, Yazaki N, Watanabe K, Haneda S, et
al: 5-fu metabolism in cancer and orally-administrable 5-fu drugs.
Cancers (Basel). 2:1717–1730. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Korbut E, Janmaat VT, Wierdak M, Hankus J,
Wójcik D, Surmiak M, Magierowska K, Brzozowski T, Peppelenbosch MP
and Magierowski M: Molecular profile of barrett's esophagus and
gastroesophageal reflux disease in the development of translational
physiological and pharmacological studies. Int J Mol Sci.
21:64362020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Su W, Feng B, Hu L, Guo X and Yu M: MUC3A
promotes the progression of colorectal cancer through the
PI3K/Akt/mTOR pathway. BMC Cancer. 22:6022022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun Y, Sun X, You C, Ma S, Luo Y, Peng S,
Tang F, Tian X, Wang F, Huang Z, et al: MUC3A promotes non-small
cell lung cancer progression via activating the NFkappaB pathway
and attenuates radiosensitivity. Int J Biol Sci. 17:2523–2536.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luo Y, Ma S, Sun Y, Peng S, Zeng Z, Han L,
Li S, Sun W, Xu J, Tian X, et al: MUC3A induces PD-L1 and reduces
tyrosine kinase inhibitors effects in EGFR-mutant non-small cell
lung cancer. Int J Biol Sci. 17:1671–1681. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu S, Zhang RF, You Y, You W, Ruan GC,
Liu YP, Zhang SY, Li Y, Feng YL, Yan XM, et al: The genomic
landscape of Cronkhite-Canada syndrome: Possible clues for
pathogenesis. J Dig Dis. 23:288–294. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hammoudeh SM, Hammoudeh AM, Bhamidimarri
PM, Al Safar H, Mahboub B, Künstner A, Busch H, Halwani R, Hamid Q,
Rahmani M and Hamoudi R: Systems immunology analysis reveals the
contribution of pulmonary and extrapulmonary tissues to the
immunopathogenesis of severe COVID-19 patients. Front Immunol.
12:5951502021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen M, Wei X, Shi X, Lu L, Zhang G, Huang
Y and Hou J: LncRNA HIF1A-AS2 accelerates malignant phenotypes of
renal carcinoma by modulating miR-30a-5p/SOX4 axis as a ceRNA.
Cancer Biol Med. 18:587–603. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zeng K, Song G, Chen B, Gao X, Liu C, Miao
J, Ruan Y, Luan Y, Chen X, Liu J, et al: Comprehensive analysis to
identify the RP11-478C19.2/E2F7 axis as a novel biomarker for
treatment decisions in clear cell renal cell carcinoma. Transl
Oncol. 25:1015252022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ye S, Li S, Qin L, Zheng W, Liu B, Li X,
Ren Z, Zhao H, Hu X, Ye N and Li G: GBP2 promotes clear cell renal
cell carcinoma progression through immune infiltration and
regulation of PD-L1 expression via STAT1 signaling. Oncol Rep.
49:492023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xie Z, Feng C, Hong Y, Chen L, Li M and
Deng W: Identification of key genes CCL5, PLG, LOX and C3 in clear
cell renal cell carcinoma through integrated bioinformatics
analysis. Front Mol Biosci. 12:15871962025. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Luo Q, Wang Q, Shi J, Lv Q, Dong Z, Li W,
Xia Y, Liu J and Yang H: PUMA reduces FASN ubiquitination to
promote lipid accumulation and tumor progression in human clear
cell renal cell carcinoma. Cell Death Dis. 16:4602025. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Miao D, Shi J, Xiong Z, Xiao W, Meng X, Lv
Q, Xie K, Yang H and Zhang X: As a prognostic biomarker of clear
cell renal cell carcinoma RUFY4 predicts immunotherapy
responsiveness in a PDL1-related manner. Cancer Cell Int.
22:662022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liang CC, Park AY and Guan JL: In vitro
scratch assay: A convenient and inexpensive method for analysis of
cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zheng M, Zhang S, Zhou J, Lin M and Liao
Y: ACAT1 suppresses clear cell renal cell carcinoma progression by
AMPK mediated fatty acid metabolism. Transl Oncol. 47:1020432024.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang X, Shi A, Liu J, Kong W, Huang Y, Xue
W, Yang F and Huang J: CDCA5-EEF1A1 interaction promotes
progression of clear cell renal cell carcinoma by regulating mTOR
signaling. Cancer Cell Int. 24:1472024. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yun Y, Ji X, Wu T, Liu Y, Li Z, Sun Z,
Zhou P, Yang L and Yu W: APOC2 promotes clear cell renal cell
carcinoma progression via activation of the JAK-STAT signaling
pathway. Curr Issues Mol Biol. 47:9362025. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shabib S, Rahnama A, Sakhtemanpour Bolouki
S, Hosseini SA and Satarzadeh M: JAK/STAT is a main signaling
pathway in renal carcinoma: A systematic review of therapeutic
potential. J Inflamm Dis. 29:e1601712025.
|
